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Aim
To analyze the validity and feasibility of the Juvenile
Arthritis Disease Activity Score [1] (JADAS)-27 in
patients with juvenile idiopathic arthritis (JIA).
Methods
1124 visits in 255 JIA patients were evaluated. Correla-
tions of JADAS-27 (range 0-57) with JADAS-10,
JADAS-71, core-set criteria, Disease Activity Index
(DAS-28), and Clinical Disease Activity Index (CDAI)
were analyzed in the total group and treatment groups.
Responsiveness to minimal clinically important differ-
ence (MCID) was analyzed longitudinally. Worsening
was defined as a flare with at least 20% PGA and 15%
ESR increase, as well as starting therapy, or drug dosage
escalation. Improvement was defined as reaching
ACRped50 or as reduction of medication.
Results
The distribution of JADAS-27 (median=2.9; range 0-40)
was skewed to the left. The JADAS-27 score could not
be calculated in 261 visits (23%), due to missing parent/
patient global assessment of well-being (n=119) or miss-
ing ESR (n=157). The JADAS-27 correlated highly with
JADAS-71 (R=1.00), JADAS-10 (R=1.00) and CDAI
(R=0.98), moderately with core set criteria (R=0.65 to
0.85) and DAS-28 (R=0.63), and poorly with ESR
(R=0.30). JADAS-27 was higher in patients using MTX
(median=4.2; p<0.001), and in patients prior to starting
anti TNF-alpha treatment (median=13.8; p<0.001).
The minimal clinically important improvement was
represented by a median change in JADAS of -5.2
(IQR= 6.6), and deterioration by +3.4 (IQR= 4.3).
Improvement was detected in 95% and worsening in
74% of visits.
Conclusion
The JADAS-27 is a reliable tool for assessing JIA disease
activity given its high correlation with other disease
activity parameters, its markedly higher scores in
patients requiring biologicals, and its ability to detect
MCID in the majority of patients. However, the high
frequency of missing values in the criteria that are
needed to calculate the JADAS-27, may hamper its
feasibility.
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